Filtz T M, Artymyshyn R P, Guan W, Molinoff P B
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia 19104-6084.
Mol Pharmacol. 1993 Aug;44(2):371-9.
Selective expression of subtypes of receptors in mammalian cell lines permits the study of the regulation of receptors in a homogeneous population of cells growing under controlled conditions. cDNAs encoding the human D2L and D2S receptors were ligated into a eukaryotic expression vector, pRc/CMV. The resulting plasmid, which contains a cytomegalovirus promoter for high expression levels, was used for stable transfection of 293 cells, a human kidney cell line. Expression of D2L and D2S receptors in 293 cells was confirmed by radioligand binding assays with [125I]NCQ 298. The pharmacological properties of the expressed receptors were comparable to those of receptors in rat striatal homogenates and in other transfected cell lines. D2L and D2S receptors were coupled to inhibition of cAMP accumulation in 293 cells. Incubation of 293-D2L cells with agonists resulted in an increase in the density of D2 receptors without a change in the affinity of the receptors for [125I]NCQ 298. This effect was time dependent, with a t1/2 of approximately 6 hr. The dose dependence of up-regulation followed the pharmacological profile expected of a D2 receptor, with an order of potency of N-propylnorapomorphine (NPA) > quinpirole > dopamine. The density of receptors was further increased by incubation of cells with agonist together with forskolin or 8-bromo-cAMP. D2S receptors responded similarly to D2L receptors to treatment with NPA and forskolin. Exposure of 293-D2L cells to the beta-adrenergic receptor agonist isoproterenol did not change the density of D2L receptors. Similarly, NPA had no effect on levels of endogenously expressed beta-adrenergic receptors in 293-D2L cells, as assayed by binding of [125I]iodocyanopindolol. Levels of beta-adrenergic receptors in transfected 293-beta 2 or 293-D2L cells did not increase after exposure to NPA but decreased after exposure to isoproterenol. Cells expressing D2L receptors were incubated with antagonists, including SCH-23390, sulpiride, haloperidol, clozapine, and epidepride, alone or in combination with NPA. Incubation of cells with SCH-23390 had no effect on the density of D2 receptors, and SCH-23390 did not block the effect of NPA. D2-selective antagonists increased the density of receptors. D2L receptor mRNA levels were unchanged during agonist treatment. This suggests a role for translational or post-translational mechanisms in the regulation of D2 receptor levels in transfected cell lines.
哺乳动物细胞系中受体亚型的选择性表达,使得在可控条件下生长的同质细胞群体中研究受体调控成为可能。编码人D2L和D2S受体的cDNA被连接到真核表达载体pRc/CMV中。所得质粒含有用于高表达水平的巨细胞病毒启动子,用于人肾细胞系293细胞的稳定转染。用[125I]NCQ 298进行放射性配体结合试验,证实了293细胞中D2L和D2S受体的表达。所表达受体的药理学特性与大鼠纹状体匀浆及其他转染细胞系中的受体相当。D2L和D2S受体与293细胞中cAMP积累的抑制相关联。用激动剂孵育293-D2L细胞导致D2受体密度增加,而受体对[125I]NCQ 298的亲和力不变。这种效应具有时间依赖性,半衰期约为6小时。上调的剂量依赖性遵循D2受体预期的药理学特征,效力顺序为N-丙基去甲阿朴吗啡(NPA)>喹吡罗>多巴胺。用激动剂与福司可林或8-溴-cAMP一起孵育细胞,可进一步增加受体密度。D2S受体对NPA和福司可林处理的反应与D2L受体相似。将293-D2L细胞暴露于β-肾上腺素能受体激动剂异丙肾上腺素,不会改变D2L受体的密度。同样,NPA对293-D2L细胞中内源性表达的β-肾上腺素能受体水平没有影响,这通过[125I]碘氰吲哚洛尔的结合来测定。转染的293-β2或293-D2L细胞暴露于NPA后,β-肾上腺素能受体水平没有增加,但暴露于异丙肾上腺素后降低。将表达D2L受体的细胞与拮抗剂(包括SCH-23390、舒必利、氟哌啶醇、氯氮平和表柔比星)单独或与NPA联合孵育。用SCH-23390孵育细胞对D2受体密度没有影响,且SCH-23390不阻断NPA的作用。D2选择性拮抗剂增加了受体密度。激动剂处理期间,D2L受体mRNA水平不变。这表明翻译或翻译后机制在转染细胞系中D2受体水平的调控中起作用。